论文部分内容阅读
目的探索改良吉西他滨联合奥沙利铂方案治疗晚期胆系肿瘤的效果。方法 120例晚期胆系肿瘤患者,随机分为观察组和对照组,各60例。对照组患者采用常规吉西他滨联合奥沙利铂方案治疗,观察组患者则采用改良吉西他滨联合奥沙利铂方案治疗。比较两组患者的临床疗效、毒副作用。结果观察组患者的治疗总有效率为38.33%,略高于对照组的35.00%,但差异无统计学意义(P>0.05);在毒副作用上,观察组患者中性粒细胞减少、恶心呕吐、脱发、肝功能损伤、血小板减少、外周神经炎的发生率均低于对照组(P<0.05);而在毒副作用的分级上,观察组患者各项毒副作用中的Ⅲ+Ⅳ级发生率略低于对照组,但差异无统计学意义(P>0.05);在生活质量上,观察组患者的提高+稳定比例明显高于对照组(P<0.05)。结论在晚期胆系肿瘤的临床治疗中,采用改良吉西他滨与奥沙利铂联合化疗方案效果显著,有助于减少化疗过程中的毒副作用,提高患者生活质量,增强患者对化疗方案的耐受力,值得推广应用。
Objective To explore the efficacy of modified gemcitabine combined with oxaliplatin regimen in the treatment of advanced biliary tumors. Methods One hundred and twenty patients with advanced biliary tumors were randomly divided into observation group and control group, with 60 cases in each group. Patients in the control group were treated with conventional gemcitabine plus oxaliplatin, while patients in the observation group were treated with modified gemcitabine plus oxaliplatin. The clinical efficacy and toxic side effects of the two groups of patients were compared. Results The total effective rate of treatment in the observation group was 38.33%, which was slightly higher than the 35.00% of the control group, but the difference was not statistically significant (P>0.05). In terms of toxic side effects, patients in the observation group had neutropenia, nausea and vomiting. The incidence of alopecia, alopecia, liver function impairment, thrombocytopenia, and peripheral neuritis were all lower than those in the control group (P<0.05). On the side of toxic and side effects, the incidence of III+IV in various toxic and side effects of the observation group was lower. Slightly lower than the control group, but the difference was not statistically significant (P> 0.05); in the quality of life, the patients in the observation group were significantly higher than the control group (P<0.05). Conclusion In the clinical treatment of advanced biliary tumors, the combination chemotherapy regimen of modified gemcitabine and oxaliplatin is effective, which can help reduce the toxic and side effects during chemotherapy, improve the patient’s quality of life, and enhance the patient’s tolerance to chemotherapy regimens. It is worth promoting.